Aligos Therapeutics (ALGS) Payables (2019 - 2026)

Aligos Therapeutics has reported Payables for 8 years, with the latest figure at $7.6 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 71.28% year-over-year to $7.6 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (up 71.28% YoY), and the FY2025 full-year result was $4.0 million, up 54.88% from the prior year.
• Payables for Q1 2026 stood at $7.6 million, up from $4.0 million in the prior quarter.
• The five-year high for Payables was $7.6 million in Q1 2026, with the low at $2.5 million in Q4 2023.
• Historically, Payables has averaged $3.8 million across 5 years, with a median of $3.2 million in 2023.
• Annual changes were most pronounced in 2023 — Payables tumbled 46.87% — and 2024, when it surged 110.4%.
• Aligos Therapeutics' Payables stood at $4.7 million in 2022, then plunged by 46.87% to $2.5 million in 2023, then climbed by 2.15% to $2.6 million in 2024, then soared by 54.88% to $4.0 million in 2025, then jumped by 91.84% to $7.6 million in 2026.
• The last three Payables figures came in at $7.6 million (Q1 2026), $4.0 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.